I just want to briefly outline in this post the power of antibody microarray when it comes to time and cost saving as well as versatility. Whether you want to do multiple profiling or quantitative studies, if you have access to only limited sample volume, if you work with “rare samples”, if you have access to laser scanner or just to a CCD camera… there is one format suited to your multiplex protein study. The whole experiment is extremely easy to perform but nothing stops you from outsourcing it to experts for the price of an extra ELISA :=). I picked as example for this post the popular inflammation arrays to illustrate the technology and give you some price examples to convince you that it’s not more expensive than an ELISA!

In a previous post, I introduced the C-series multiplex profiling technology from Raybiotech, a smart way to multiplex your western blot while saving time and sample volume, and decreasing the cost of your experiment. Indeed, one blot for multiple targets processed at once is a nice way to boost your protein profiling studies! I just wanted to highlight in this post, that on top of the standard species models like human, mouse and rat, these C-series are also available for many other models. With 15 different species to select from, RayBiotech is leading the way for immunoassay kit species diversity.

In a previous post, I introduced several biomarker arrays & assays, companion tools for biomarker discovery, monitoring and quantification. Today, I will focus more specifically on high density proteomics microarrays. This post aims at helping you understand what services are available in this domain and how they could fit within your project.

Indeed, tebu-bio has just been appointed by RayBiotech as one of the 3 companies worldwide to perform contract research on their recently developed higher density proteomics tools. A good opportunity to talk about this!

On your journey to Biomarker profiling, you will reach the point where you need to quantify the proteins of interest identified along the way (eg. validation of semi-quantitative array results; biomarker discovery with an initial hunch on which pathway is involved).

At this stage, you will have narrowed down the number of targets you want to look at. However, the use of ELISAs is likely to be still too costly, too time consuming, and may require too much sample volume.